Skip to main content
Clare Murray on Muck Rack

Clare Murray

Cornhill
As seen in: Forbes, Nature, Wiley Online Library, PLOS Medicine, PLOS ONE, BMJ Open, MDPI, The BMJ, Thorax, Law.com and
UK Employment & partnership lawyer;slightly overindulgent mum.Views expressed are personal & not those of my firm.A retweet does not indicate my views
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Clare

Contact Clare, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

When Agreements Collide — The Ontario Court Of Appeal Upholds Forum Selection Provision In Friel v. HUB

|
By Amanda McLachlan, Clare Murray
| Mondaq
Bennett Jones LLP are most popular: within Insurance, Coronavirus (COVID-19) and Compliance topic(s) with Inhouse Counsel in Canada with readers working within the Business & Consumer Services, Healthcare and Technology industries In Friel v.
Open in Who Shared Issue with article?

When Agreements Collide - The Ontario Court of Appeal Upholds Forum Selection Provision in Friel v. HUB | JD Supra

|
By Clare Murray
| JD Supra
In Friel v. HUB International Limited, 2026 ONCA 313, the Ontario Court of Appeal upheld the enforceability of a forum selection clause designating the State of Delaware as the exclusive forum for resolving a dispute between a former employee in Ontario and his employer's Delaware-based parent entities over the exercise of vested share options.
Open in Who Shared Issue with article?

Safety and immunogenicity of concomitant quadrivalent meningococcus ACYW-TT and meningococcus group B vaccines

|
By Monica McArthur, Adam Finn, Lawrence Barnes, Katrina Cathie, Eva P. Galiza, Paul Heaton, Nicholas Jacobsen, Stephen Jones, Siân Ludman, Patrick Moore, Clare Murray, Daniel Owens, Ray Borrow, Julie Chaix, Youjun Huang, Olga Syrkina, Betzana Zambrano, Mandeep Singh Dhingra, Christine Rehm, Richard Burkimsher, Alexander Trotman, Arlette Delgado, Estelle Dubois
| Nature Verified
Abstract Infants are vulnerable to meningococcal disease. In this open-label phase III study (NCT03632720; registered 13/8/2018), infants were randomised to quadrivalent ACWY conjugated vaccine, MenACYW-TT, at 3 and 12–13 months and four-component meningococcus group B vaccine (4CMenB) at 2, 4, and 12–13 months (Group 1), MenACYW-TT at 3 and 12–13 months and 4CMenB at 2 and 4 months (Group 2), or 4CMenB at 2, 4, and 12–13 months (Group 3). Routine vaccines were also administered per UK schedule.
Open in Who Shared Issue with article?
See all 63 licensed articles (67 Total)